LPX-TI641 not checked

LAPIX Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Atopic Dermatitis (AD), Psoriasis (PsO), Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Main trialPhase 1
“The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.”In the company’s words, NCT06982352 on ClinicalTrials.gov

Other drugs for Atopic Dermatitis (AD)

All 90 drugs for Atopic Dermatitis (AD)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 15 Jan 2026 Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
Phase 1Active, not recruiting 15 Nov 2026 Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
Phase 1Completed 15 Aug 2024 First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow LPX-TI641

Following is part of Solo: you see every change to LPX-TI641 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in